(Q38014916)

27 August 2017

title

Therapeutic strategies for the prevention and treatment of cytomegalovirus infection (English)

1 reference

27 August 2017

0 references

Rob S Sellar

1

1 reference

27 August 2017

Karl S Peggs

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1161-1172

1 reference

Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Cytomegalovirus and human immunosenescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Management of multidrug-resistant viruses in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Artesunate combinations for treatment of malaria: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Adoptive T cell immunotherapy for cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Adoptive cellular immunotherapy for viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

CMV-specific TCR-transgenic T cells for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

Cytomegalovirus‐Specific Cellular Immune Responses and Viremia in Recipients of Allogeneic Stem Cell Transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.693471

10.1517/14712598.2012.693471

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference